Diagnostic and therapeutic status of haemophilia in Latin America

1. Shapiro AD. A global view on prophylaxis: possibilities and consequences. Haemophilia 2003; 9 Suppl 1: 10V7.10.1046/j.1365-2516.9.s1.2.x12709032Search in Google Scholar

2. Stonebraker JS, Brooker M, Amand RE, et al. A study of reported factor VIII use around the world. Haemophilia 2010; 16W1X: 33V46.10.1111/j.1365-2516.2009.02131.x19845774Open DOISearch in Google Scholar

3. MancoVJohnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357W6X: 535V44.Search in Google Scholar

4. National Hemophilia Foundation Medical Bulletin 1994, 193.Search in Google Scholar

5. World Health Organization. Report of a joint WHO and WFH Meeting on the control of hemophilia: Modern treatment of hemophilia. WHO; Geneva, 1994.Search in Google Scholar

6. KruseVJarres R. Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia 2013; 19 Suppl 1: 2V7.10.1111/hae.1204923278993Search in Google Scholar

7. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasmaVderived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8W6X: 1256V65.10.1111/j.1538-7836.2010.03823.x20345722Search in Google Scholar

8. Santagostino E, Morfini M, Auerswald GK, et al. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia 2009; 15W5X: 983V9.10.1111/j.1365-2516.2009.01999.x19712172Open DOISearch in Google Scholar

9. Rothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000; 84W1X: 145V6.10.1055/s-0037-1613988Search in Google Scholar

10. Lenk H; ITT Study Group. The German Registry of immune tolerance treatment in hemophiliaVV1999 update. Haematologica 2000; 85W10 SupplX: 45V7.Search in Google Scholar

11. Ettingshausen CE, Kreuz W. The immune tolerance induction WITIX dose debate: does the International ITI Study provide a clearer picture? Haemophilia 2013; 19 Suppl 1: 12V7.10.1111/hae.1205123278995Search in Google Scholar

12. Brackmann HH, Schwaab R, Effenberger W, et al. Antibodies to factor VIII in hemophilia A patients. Vox Sang 2000; 78 Suppl 2: 187V90.Search in Google Scholar

13. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16 Suppl 1: S27V31.10.1097/01.mbc.0000167660.30886.e915849524Open DOISearch in Google Scholar

14. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7W4X: 375V80.10.1046/j.1365-2516.2001.00530.x11442642Open DOISearch in Google Scholar

15. Berntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica 2003; 88W6X: EREP03.Search in Google Scholar

16. Suzuki T, Arai M, Amano K, et al. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996;76W5X: 749V54.10.1055/s-0038-1650655Search in Google Scholar

17. Gensana M, Altisent C, Aznar JA, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7W4X: 369V74.10.1046/j.1365-2516.2001.00526.x11442641Open DOISearch in Google Scholar

18. Astermark J, Voorberg J, Lenk H, et al. Impact of inhibitor epitope profile on the neutralizing effect against plasmaVderived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9W5X: 567V72.10.1046/j.1365-2516.2003.00802.x14511295Open DOISearch in Google Scholar

19. Inoue T, Shima M, Takeyama M, et al. Higher recovery of factor VIII WFVIIIX with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor. Haemophilia 2006; 12W1X: 110V3.10.1111/j.1365-2516.2006.01182.x16409188Open DOISearch in Google Scholar

20. Kreuz W, EscuriolaVEttingshausen C, Auerswald G, et al. Immune tolerance induction WITIX in haemophilia A V patients with inhibitors V the choice of concentrate affecting success. Haematologica 2001; 86WS4X: 16V22.Search in Google Scholar

21. Auerswald G, Spranger T, Brackmann HH. The role of plasmaVderived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88W6X: EREP05.Search in Google Scholar

22. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96W5X: 1698V702.10.1182/blood.V96.5.1698Search in Google Scholar

23. Teitel JM, Barnard D, Israels S, et al. Home management of haemophilia. Haemophilia 2004; 10W2X: 118V33.10.1046/j.1365-2516.2003.00853.x14962201Search in Google Scholar

24. Soucie JM, Symons J 4th, Evatt B, et al. HomeVbased factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001; 7W2X: 198V206.10.1046/j.1365-2516.2001.00484.x11260280Open DOISearch in Google Scholar

25. Kurth MA, Dimichele D, Sexauer C, et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14W1X: 50V5.Search in Google Scholar